ÖZET
Amaç:
Dihidroartemisinin-Piperaquine (DHP) kombinasyonu, Endonezya’da komplike olmayan sıtma için birinci basamak tedavidir ve 2010 yılından beri kullanılmaktadır. Bu çalışma, toplum temelli bir değerlendirmede komplike olmayan sıtma tedavisi için DHP kombinasyonunun etkinliğini belirlemek için yapılmıştır.
Yöntemler:
Çalışmaya katılım, aktif veya pasif olgu tespiti ile yapıldı. Komplike olmayan tüm sıtma hastaları günde bir kez üç gün boyunca ağızdan DHP ile tedavi edildi (birinci basamak sağlık hizmetinde yapıldığı gibi). Hastalar tedavi sonrası 28. güne kadar takip edildi. Birincil son nokta 28 günlük bir iyileşme oranıydı.
Bulgular:
Bu çalışmada 484 denek aktif ve pasif olgu tespiti ile tarandı. P. vivax ile enfekte olan toplam 45 denek ve P. falciparum ile enfekte olan iki denek, yazılı bilgilendirilmiş onam ile katılmayı kabul etti. Analiz edilen tüm özelliklerde klinik sıtma ile asemptomatik sıtma arasında hiçbir fark yoktu. Bir hastanın D3 parazit yoğunluğu %25 D0’dan daha yüksek olmasına rağmen ertesi gün parazit bulunmadı (D4). Bu çalışmada, yeterli klinik ve parazitolojik yanıtlara sahip 46 hasta (%97,9) bulundu. Çalışmanın takibi sırasında herhangi bir advers olay bildirilmedi.
Sonuç:
DHP, birinci basamak sağlık hizmetlerinde komplike olmayan sıtmanın tedavisinde etkili, güvenlidir ve iyi tolere edilmektedir.
References
1
World Health Organization. Guidelines for The Treatment of Malaria. Geneva. 2015.
2
World Health Organization. Antimalarial Drug Combination Therapy. Report of a WHO Technical Consultation. World Health Organization. Geneva. 2001.
3
Thwing JI, Odero CO, Odhiambo FO, Otieno KO, Kariuki S, Ord R, et al. In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health 2009; 14: 294-300.
4
Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis 2007; 44: 1067-74.
5
Siahaan L, Yuniarti T, Juliani I, Darmawan P. PerbandinganBeberapaKombinasi Artesunate Pada Pengobatan Malaria Falciparum TanpaKomplikasi. Simposium Nasional Parasitologi Dan PenyakitTropis. Denpasar, 25-26 Agustus 2007.
6
Tjitra E, Delima D, Hasugian AR, Siswantoro H, Avriana R, Sampurno OD. Efficacy and safety of dihydroartemisinin-piperaquine in Indonesia children infected with uncomplicated Plasmodium falciparum and Plasmodium vivax, Paediatrica Indonesiana 2011; 51: 351-60.
7
World Health Organization. Monitoring Antimalarial Drug Resistance. Report of a WHO Consultation. Geneva 2001: 9-21.
8
Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T, Proux S, et al. A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis 2005; 41: 425-32.
9
Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung RM, Laihad F, et al. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 2007; 369: 757-65.
10
Pasaribu AP, Chokejindachai W, Sirivichayakul C, Tanomsing N, Chavez I, Tjitra E, et al. A randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine combined with primaquine for radical treatment of vivax malaria in Sumatera, Indonesia. J Infect Dis 2018; 208: 1906-13.
11
Krudsood S, Looareesuwan S, Tangpukdee N, Wilairatana P, Phumratanaprapin W, Leowattana W, et al. New fixed-dose artesunate-mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed artesunate plus mefloquine. Antimicrob Agents Chemother 2010; 54: 3730-7.
12
Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother 2010; 54: 52-9.
13
Sirivichayakul C, Sabchareon A, Pengsaa K, Thaiarporn I, Chaivisuth A, Na-Bangchang K, et al. Comparative study of the effectiveness and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for the treatment of uncomplicated childhood falciparum malaria. Ann Trop Paediatr 2007; 27: 17-24.
14
Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansané A, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 2009; 8: 200.
15
German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47: 91-102.
16
Karunajeewa H, Lim C, Hung TY, Ilett KF, Denis MB, Socheat D, et al. Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol 2004; 57: 93-9.
17
Wang Y, Yang Z, Yuan L, Zhou G, Parker D, Lee MC, et al. Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border. Am J Trop Med Hyg 2015; 93: 577-83.
18
Zwang J, Ashley EA, Karema C, D’Alessandro U, Smithuis F, Dorsey G, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009; 4: e6358.
19
Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg 2007; 101: 858-66.
20
Janssens B, van Herp M, Goubert L, Chan S, Uong S, Nong S, et al. A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health 2007; 12: 251-9.
21
Lidia K, Deo DA, Pakan PD, Riwu M. Evaluation of therapeutic efficacy and safety of Dihydroartemisinin-Piperaquine in uncomplicated Plasmodium falcifarummonoinfection in Timor Tengah Selatan district, Nusa Tenggara Timur, Indonesia. Southeast Asian J Trop Med Public Health 2018; 49: 733-40.
22
Wang Q, Zhang Z, Yu W, Lu C, Li G, Pan Z, et al. Surveillance of the Efficacy of Artemisinin-Piperaquine in the Treatment of Uncomplicated Plasmodium falciparum Malaria Among Children Under 5 Years of Age in Est-Mono District, Togo, in 2017. Front Pharmacol 2020; 11: 784.
23
Chotsiri P, Zongo I, Milligan P, Compaore YD, Somé AF, Chandramohan D, et al. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nat Commun 2019; 10: 480.
24
Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba D, Mulenga M, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011; 10: 50.
25
Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, et al. Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg 2006; 100: 1105-11.
26
Tangpukdee N, Krudsood S, Thanachartwet W, Chalermrut K, Pengruksa C, Srivilairit S, et al. An open randomized clinical trial of Artekin vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health 2005; 36: 1085-91.
27
Commons RJ, Simpson JA, Thriemer K, Abreha T, Adam I, Anstey NM, et al. The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Med 2019; 16: e1002928.
